Dr. Shaukat on the Methods Utilized in the PREEMPT-CRC Trial in CRC

Aasma Shaukat, MD, MPH, Robert M. and Mary H. Glickman professor of Medicine and Gastroenterology, Department of Medicine, professor, Department of Population Health, co-director, Translational Research Education and Careers, director, Outcomes Research, Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, discusses the methods utilized in the PREEMPT CRC trial (NCT04369053) in colorectal cancer (CRC).

PREEMPT CRC is a prospective, multi-center, observational trial evaluating a blood-based test for its ability to detect CRC. Samples are collected from average-risk patients receiving a routine screening colonoscopy.

The study is designed to validate the blood-based test by comparing results against those from a standard colonoscopy, which is still considered the gold standard for screening for CRC, Shaukat says. In addition to being average risk, all patients are at least 45 years old who are scheduled to undergo a screening colonoscopy, Shaukat explains.

The blood test is administered prior to the colonoscopy, and patients provide basic background information as a part of the study, Shaukat continues. The main goal of the study is to evaluate the accuracy of the blood-based test, specifically in its ability to detect advanced adenomas and early CRC, Shaukat concludes.